Collegium Gets European Patent Allowance Covering Its Xtampza

Collegium Pharmaceutical, Inc.

revealed that it has been issued an intention of grant letter by the European Patent Office covering Xtampza (oxycodone) extended-release (ER) capsules. The specialty pharmaceutical company focused on developing and commercializing innovative abuse-deterrent treatments for chronic pain and other diseases said that Xtampza ER is its first product using the DETERx technology platform. The company indicated that it has eight patents that are listed in the FDA Orange Book in the United State currently apart from issued patents in Canada, Japan and Australia. Collegium's Chairman and CEO, Michael Heffernan, said, "This patent application is part of Collegium's expanding patent portfolio covering Xtampza ER and the DETERx technology platform. Building an international patent portfolio is an important part of our growth strategy outside of the U.S. We continue to evaluate business development opportunities for our product portfolio in key international markets such as Canada, Japan, Australia, and Europe, amongst others." The stock edged up by $0.05 or 0.41 percent to trade at $12.18 on Monday.